ProCE Banner Series

Clinical Considerations in RCC: Evidence, Guideline Recommendations, and a View to the Future

Join us live or via simulcast for this CME-certified symposium featuring expert discussion of current best practices, guideline recommendations, and recent and emerging data in treating patients with renal cell carcinoma across the adjuvant, first-line, and second-line settings. This activity will feature interactive patient case scenarios and dynamic question and answer sessions. Sign up now!

To Register: Please click the green “Learn More” button below. On the next page, select either Register for In-Person Event or Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

For more information on ASCO’s Health and Safety policy for this event, please visit ASCO’s website.

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

Who Should Attend

This educational program is intended for oncologists, physician assistants/physician associates, nurses, pharmacists, and other healthcare professionals involved in the care of patients with RCC.

All Events

Clinical Considerations in RCC: Evidence, Guideline Recommendations, and a View to the Future

Past Events




ProCE Banner

7:00 PM - 9:00 PM Central Time (CT)

In-person | Virtual

Hilton Chicago, 720 South Michigan Avenue, Chicago, Illinois 60604


ProCE Banner Faculty
Katy Beckermann, MD, PhD

Assistant Professor
Department of Internal Medicine
Division of Hematology/Oncology
Vanderbilt University
Nashville, Tennessee

ProCE Banner Faculty
Stephanie A. Berg, DO

Instructor of Medicine
Genitourinary Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

ProCE Banner Faculty
Toni K. Choueiri, MD

Director, Lank Center for Genitourinary Oncology
Medical Director, International Strategic Initiatives
Dana-Farber Cancer Institute
Co-Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Professor of Medicine
Harvard Medical School
Boston, Massachusetts 


  • Welcome and introduction
  • Non-metastatic RCC at initial diagnosis
  • First line therapies in advanced or metastatic RCC
  • NCCN resources for patients
  • Second line therapy and beyond
  • Management of adverse events associated with immunotherapy-based combinations for advanced RCC
  • Looking ahead: ongoing clinical trials
  • Final panel discussion and audience question and answer session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.


Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with RCC. 

Target Audience
This educational program is intended for oncologists, physician assistants/physician associates, nurses, pharmacists, and other healthcare professionals involved in the care of patients with RCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients with RCC most likely to benefit from targeted and/or immune checkpoint inhibitor–based combination therapies based on risk and biomarker assessment, along with patient medical and treatment history
  • Select optimal first-line treatment for individual patients with advanced or metastatic RCC, considering current and emerging options, available clinical evidence, expert recommendations, and patient preferences
  • Plan evidence-based and expert recommended therapeutic sequencing strategies for patients with RCC
  • Manage specific disease-related complications or adverse events associated with currently approved treatments for advanced RCC
  • Select patients with RCC who may benefit from ongoing clinical trials based on tumor characteristics, previous treatment, and patient characteristics and preferences


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 2.0 contact hours. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. UAN: JA4008196-0000-23-031-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Attention Pharmacists:
Attention Pharmacists: You must complete the evaluation within 30 days of the activity for continuing pharmacy education credit to be reported to the CPE Monitor. Be sure to enter your NAPB e-profile ID and date of birth when prompted in the evaluation or your credit cannot be reported. If you have not already done so, please complete your e-profile at to obtain your NABP e-Profile ID. 

Physician Assistants 

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Conflicts of Interest 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 


Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC.

Supported by educational grants from AVEO Pharmaceuticals, Inc. (“AVEO Oncology”) and Eisai.

Supported by a medical education grant from Exelixis, Inc.